BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37416990)

  • 1. Coexisting Genomic Alterations in Risk Stratification of KRASG12C-Mutated Non-Small Cell Lung Cancer.
    Heng SZW; Hoo R; Tan DSW
    Cancer Discov; 2023 Jul; 13(7):1513-1515. PubMed ID: 37416990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
    Negrao MV; Araujo HA; Lamberti G; Cooper AJ; Akhave NS; Zhou T; Delasos L; Hicks JK; Aldea M; Minuti G; Hines J; Aredo JV; Dennis MJ; Chakrabarti T; Scott SC; Bironzo P; Scheffler M; Christopoulos P; Stenzinger A; Riess JW; Kim SY; Goldberg SB; Li M; Wang Q; Qing Y; Ni Y; Do MT; Lee R; Ricciuti B; Alessi JV; Wang J; Resuli B; Landi L; Tseng SC; Nishino M; Digumarthy SR; Rinsurongkawong W; Rinsurongkawong V; Vaporciyan AA; Blumenschein GR; Zhang J; Owen DH; Blakely CM; Mountzios G; Shu CA; Bestvina CM; Garassino MC; Marrone KA; Gray JE; Patel SP; Cummings AL; Wakelee HA; Wolf J; Scagliotti GV; Cappuzzo F; Barlesi F; Patil PD; Drusbosky L; Gibbons DL; Meric-Bernstam F; Lee JJ; Heymach JV; Hong DS; Heist RS; Awad MM; Skoulidis F
    Cancer Discov; 2023 Jul; 13(7):1556-1571. PubMed ID: 37068173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
    Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS
    Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
    Alessi JV; Elkrief A; Ricciuti B; Wang X; Cortellini A; Vaz VR; Lamberti G; Frias RL; Venkatraman D; Fulgenzi CAM; Pecci F; Recondo G; Di Federico A; Barrichello A; Park H; Nishino M; Hambelton GM; Egger JV; Ladanyi M; Digumarthy S; Johnson BE; Christiani DC; Lin X; Gainor JF; Lin JJ; Pinato DJ; Schoenfeld AJ; Awad MM
    J Thorac Oncol; 2023 Jun; 18(6):731-743. PubMed ID: 36775193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer.
    Liao R; Chen K; Li J; He H; Yi G; Huang M; Chen R; Shen L; Zhang X; Xu Z; Yang Z; Peng Y
    Cancer Res Treat; 2023 Jul; 55(3):814-831. PubMed ID: 36634615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
    Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
    Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma.
    Song S; Nguyen V; Schrank T; Mulvaney K; Walter V; Wei D; Orvis T; Desai N; Zhang J; Hayes DN; Zheng Y; Major MB; Weissman BE
    Mol Cancer Res; 2020 Dec; 18(12):1777-1788. PubMed ID: 32855269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
    Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV
    Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the tumor microenvironment cell-infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC.
    Chen H; Zhang T; Zhang Y; Wu H; Fang Z; Liu Y; Chen Y; Wang Z; Jia S; Ji X; Shang L; Du F; Liu J; Lu M; Chong W
    JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35511432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
    Cortellini A; Ricciuti B; Borghaei H; Naqash AR; D'Alessio A; Fulgenzi CAM; Addeo A; Banna GL; Pinato DJ
    Cancer; 2022 Aug; 128(16):3067-3079. PubMed ID: 35727053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Landscape of
    Salem ME; El-Refai SM; Sha W; Puccini A; Grothey A; George TJ; Hwang JJ; O'Neil B; Barrett AS; Kadakia KC; Musselwhite LW; Raghavan D; Van Cutsem E; Tabernero J; Tie J
    JCO Precis Oncol; 2022 Mar; 6():e2100245. PubMed ID: 35319967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.
    Cai R; Zhu H; Liu Y; Sha H; Peng W; Yin R; Zhou G; Fang Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10027-10040. PubMed ID: 37261523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
    Wang H; Shan Q; Guo J; Han X; Zhao C; Li H; Wang Z
    Lung Cancer; 2021 Jan; 151():76-83. PubMed ID: 33246647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
    Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
    PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Pathological Characteristics of
    Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
    Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
    Nambirajan A; Jain D
    Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Sabari JK; Velcheti V; Shimizu K; Strickland MR; Heist RS; Singh M; Nayyar N; Giobbie-Hurder A; Digumarthy SR; Gainor JF; Rajan AP; Nieblas-Bedolla E; Burns AC; Hallin J; Olson P; Christensen JG; Kurz SC; Brastianos PK; Wakimoto H
    Clin Cancer Res; 2022 Aug; 28(15):3318-3328. PubMed ID: 35404402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.